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Liquid biopsy has the potential to provide information about cancers without invasive biopsy, using
circulating biomarkers. These include proteins, RNA and DNA. They can be used in detection, diagnosis,
monitoring and detection of recurrence. While protein-based tumour markers have been used in routine
pathology for many years, the ability to detect mutations in circulating DNA is relatively new, and poised
to enter clinical practice. A number of issues remain, and it is important that such markers are fully
validated before they enter clinical practice. Evidence of clinical utility and cost effectiveness are major
hurdles, but it is likely that the use of liquid biopsy in deﬁned settings could beneﬁt cancer patients
substantially.
Copyright © 2015 The Author. Published by Elsevier Ltd on behalf of The Royal College of Pathologists.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Blood-based biomarkers (liquid biopsy) in cancer have considerable potential for the initial detection, diagnosis andmonitoring of cancer
[1]. Circulating tumour cells (CTC), circulating tumour DNA (ctDNA) and microRNA (miRNA) are all options, alongside existing and new pro-
tein markers. CTCs are present in the peripheral blood of patients with most types of advanced cancer, but there is uncertainty around the
sensitivity of CTCs in low volume disease in comparisonwith ctDNA or miRNA [2e4]. ctDNA levels reﬂect tumour load, and increased levels
can be found in pre-malignancy [5]. ctDNA permits the detection of mutations, which can be used to guide therapy [6], and altered gene
methylation. miRNA signatures are providing promising results for cancer detection, though their ability to predict response to therapy
is uncertain [7].
DNA-basedmarkers have considerable potential. We and others have shown that cfDNA appears in blood from tumours at an early stage,
and is produced by benign tumours (adenomas) as well as invasive carcinomas [5]. Within ctDNA there is now a considerable literature
showing that mutations, including those of relevance to treatment choice, can be detected with high sensitivity and speciﬁcity [6]. This in-
cludes fusion genes. While changes in copy number are more difﬁcult to assess, this has been donewith some successe though at consider-
able cost [8]. Changes in methylation occur within ctDNA and such assays may be clinically as well as technically feasible [9,10].
In contrast to DNA, RNA is often thought of as very labile and difﬁcult to work with. While this may be true of cytokine mRNA in partic-
ular, it is less so for some other types of RNA, as follows.
1. miRNA: a number of groups have published data showing that miRNA proﬁles in plasma and serum have good sensitivity and speciﬁcity
for cancer diagnosis [7,11,12].
2. RNA from plasma exosomes and CTCs which can be used for RNA sequencing, permitting the identiﬁcation of fusion genes from RNA as
well as DNA.
3. RNA from blood leukocytes permits identiﬁcation of immunological reactions to cancer, whichmay become of considerable future impor-
tance, particularly for patients on immunotherapy (e.g. anti-CTLA4).
The classical tumour markers in clinical practice are mostly proteins. Tumour markers are particularly important in following the
response of patients to treatment, and making an early diagnosis of relapse. These molecules are used in initial diagnosis (usually in com-
bination with imaging and other diagnostics), though they are less than successful in this role. With a few exceptions, such as CA125 in
ovarian cancer, these markers are not speciﬁc to a particular cancer type. They are however regarded as the standard that new biomarkers
need to exceed to be clinically useful, and can act as a useful gold standard for studies.
The appearance of neoplastic cells in blood is unsurprising as it is a requirement for metastasis. Moreover, in most tumours types, the
number present reﬂects the stage of the tumour: low stage tumours with limitedmetastatic ability have low numbers of circulating tumour
cells (CTC), while advanced tumours may have many CTC. CTCs contain intact DNA, RNA and proteins, and arguably represent clones within
the tumour with metastatic potential. They have therefore considerable diagnostic potential, at least in advanced disease.y Elsevier Ltd on behalf of The Royal College of Pathologists. This is an open access article under the CC BY-NC-ND li-
/4.0/).
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It is debatable which of these sources best identify markers of most importance, but the reality is that all have potential to replace stan-
dard biopsy in various patients, as follows:
1. Biopsy of any cancer is a surgical procedure and inherently more risky to the patient than taking a blood sample.
2. It is difﬁcult and often impossible to take further biopsies during treatment due to risk to the patient.
3. Tumours show intra-tumoural heterogeneity and clones within the tumour may arise showing different behavior.
We would add a fourth issue: that of affordability to hard-pressed healthcare systems. A transthoracic needle biopsy under CT control
may cost around £400, which is more than enough to pay for several of the assays considered above.
It is therefore no surprise that very few blood biomarkers have entered practice over the last 25 years, with the possible exceptions of
serumHER2neu and S100, which are not widely used. Most clinical laboratories offer a handful of tumourmarkers, usedmainly during treat-
ment to monitor response. Yet, over that period a recent search returned over 200,000 references in the scientiﬁc literature [13]. The ma-
jority of these are small case control studies, and provide basic analytic validation rather than the clinical validation and demonstration of
utility required for implementation by bodies such as the UK National Institute for Health and Care Excellence (NICE), which has pioneered
the use of health economics to justify the introduction of tests to clinical practice within its Diagnostics Assessment Programme.
NICE have been disappointed to ﬁnd that many tests on the market lack robust analytical and clinical validation data, let alone evidence
of cost effectiveness and clinical utility. This has made it impossible to recommend tests for uptake, and NICE have not yet looked at any new
tumour biomarkers in blood. Other countries have similar concerns and the forthcoming IVD directive is widely expected to restrict the use
of non-CE marked ‘in house’ or ‘homebrew’ tests to those laboratories accredited to ISO15189.
Automation provides affordability for pathology laboratories and is key to the uptake of these methods in blood sciences. In addition to
large analysers, lab-on-chip technologies are coming of age and are particularly promising in CTC analysis. Several EU programmes have
addressed the development of microﬂuidic devices for CTCs.
The question is whether any of the blood-based biomarkers have sufﬁcient evidence to enter clinical practice in anything other than a
research setting. Samples from the patient pathway, from diagnosis to recurrence allow a large number of different diagnostic assays. It is
clear that liquid biopsy has a place, but it must be embedded within patient pathways and cross-validation with existing tests is a pre-
requisite for implementation.
3. Current technologies available
3.1. DNA
The presence of cfDNA in blood from cancer patients has been known since the 1970s [14], but methods for its detection and analysis
have now advanced to the point where clinical trials are showing its utility for the detection of actionable mutations as companion diag-
nostics, and as a means of monitoring response to treatment. Extraction of DNA from plasma is preferred over serum, and can be accom-
plished usingmanual or automatedmethods (e.g. Qiagen, Siemens, Promega). For routine laboratory use, automatedmethods havemuch to
recommend them in terms of reproducibility and cost effectiveness.
There are a number of PCR-based kits on the market, which can detect cfDNA generically, using LINE1 or ALU repeats to determine the
fragment size [5,15]. A commercial version of this is under development. To determine that the cfDNA is actually tumour-derived (ctDNA)
requires the demonstration of mutations present in the tumour, or methylation of key tumour genes (e.g. RASSF1A) [16]. These are feasible
using PCR methods, and commercially available PCR-based mutation detection systems will detect a proportion of patients known to have
mutations in their tumours. Improved methods under development by a number of laboratories have taken the sensitivity to 0.01% mutant
in wild-type DNA and are being tested for use in clinical practice, with early clinical validation results showing excellent tumour-plasma
concordance [17]. Intriguingly, it is also possible to use ELISA methods to detect methylated DNA (Volition SA, Belgium).3.2. RNA
PCR-based methods are used to look for miRNA in plasma and several reports suggest that this is robust method for the detection of
relapse, even early cancer detection [7,11,12]. A recent study demonstrated that Droplet Digital PCR technology improved day-to-day repro-
ducibility of quantifyingmiRNA in serum from patients seven-fold relative to qPCR [18]. However, it is worth noting that several groups have
had less success, and there may be a need for non-standard handling of blood samples for miRNA, which may make routine clinical use of
this promising technology difﬁcult.3.3. Proteins
Themeasurement of protein tumourmarkers in serum is standard in most hospitals to monitor patient progress, and represents the gold
standard for this against which other methods must be compared [19]. Most clinical centres will have the following tests available: AFP,
CA125, CEA, CA15-3, CA19-9 and PSA. Some are likely to have CA72-4, HE-4, CYFRA21-1, S100, NSE, SCCA, sHER2, and ProGRP, all of which
are available as ELISAs. There is evidence that thymidine kinase, circulating nucleosomes and the immunogenic cell death markers, high-
mobility group box 1 (HMGB1), soluble receptors of advanced glycation end products (sRAGE) and DNAse activity are also useful [20]. The
advantage of such methods is that they are simple and relatively inexpensive. However, to be truly useful, there is a need for multiplex mea-
surement and analysis, which can be difﬁcult.
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A simple PubMed search for ‘circulating tumor cells blood’ shows 9179 references. Several recent reviews have been published, including
a few systematic reviews, and many methods are available [21e23]. These are based on the physical properties (e.g. size or shape) of the
cells, or their biology (e.g. adhesion molecule expression). Methods for isolation include CTC microchips, ﬁltrations systems, and bead-
based capture, while a variety of PCR and cytological methods are used for analysis. Veridex (now part of Janssen) is the leader in the ﬁeld
and has awell established technology, CellSearch™, which is widely used in research studies (245 references) and some clinical trials, and a
recent meta-analysis in metastatic breast cancer [24,25]. It is FDA approved for use in breast cancer to monitor treatment (www.
cellsearchctc.com). It has limitations since living cells cannot be obtained and it is difﬁcult to undertake molecular studies. Numbers of
CTC isolated by CellSearch tend to be fewer than those found with other technologies, but there is concern that some of these confuse
neoplastic cells with other cells, such asmacrophages, whichmay carry similar markers. Recent studies suggest that CTCs show considerable
molecular heterogeneity, and capture of cells that have an altered phenotype is challenging, as is knowing which are clinically relevant. At-
tempts to increase sensitivity and therefore utility in low volume disease run the risk of decreasing speciﬁcity for CTCs. Awide range of other
methods are available or under development, and many are being commercialised, though only for research use [26]. The paper by Hong &
Zu [26] considers a wide range of methods (15 are listed) and shows a lack of clinical validation data for seven of these. Different consortia
are developing automated microﬂuidic cell isolation and biomarker (mostly molecular, multiplexed) analysis in one system, but are
hampered by the fact that there is little clinical consensus on the biomarker set to be automated. There are few comparative studies and
systematic reviews show that most studies are too small to be considered to provide sufﬁcient validation to permit clinical implementation
[23].
4. Conclusion
Liquid biopsy is a rapidly advancing ﬁeld and the subject of intense interest from both academia and industry. Implementation within
pathology is likely and the ability to improve diagnosis from less invasive blood tests has the potential to improve the management of many
cancer patients.
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